Brief: IRLAB To Advance Clinical Development Of IRL790 In LIDs
28/08/2019 06:09
Aug 28 (Reuters) - IRLAB Therapeutics AB IRLABa.ST :
* IRLAB TO ADVANCE CLINICAL DEVELOPMENT OF IRL790 IN LIDS BASED ON IN-DEPTH ANALYSIS OF
POSITIVE
PHASE IIA RESULTS
* IN-DEPTH ANALYSIS OF DATA FROM RECENTLY CONCLUDED PHASE IIA STUDY OF IRL790 IN PARKINSON'S
PATIENTS WITH L-DOPA INDUCED DYSKINESIA (LIDS) BRINGS FURTHER EVIDENCE OF DRUG CANDIDATE'S
ABILITY TO SIGNIFICANTLY AND MEANINGFULLY IMPROVE DAYTIME MOVEMENT QUALITY
* DECIDED TO PRIORITIZE LIDS INDICATION IN DEVELOPMENT OF IRL790
* A PHASE IIB/III STUDY IN THIS PATIENT GROUP IS PLANNED TO START IN FIRST HALF OF 2020
Source text for Eikon: ID:nWkr2js86M
Further company coverage: IRLABa.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))